



Atty. Dkt. No. 034827-1303

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Doug Hui Huang
Title: HIGH THROUGHPUT
CYTOCHROME P450
GENOTYPING
Appl. No.: 10/615,497
Filing Date: 07/07/2003
Examiner: Unknown
Art Unit: 1632

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450, on the date below.	
<u>DIANE GARCIA</u> (Printed Name)	
<u>Diane Garcia</u> (Signature)	
1-22-04 (Date of Deposit)	

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document, except as noted below, is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, *Information Disclosure Statements May Be Filed Without*

Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even

entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.


Respectfully submitted,

Date 1/21/04

By Barry Wilson

FOLEY & LARDNER
Customer Number: 30542
Telephone: (858) 847-6722
Facsimile: (858) 792-6773

Barry S. Wilson
Attorney for Applicant
Registration No. 39,431



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

10

Complete if Known

Application Number	10/615,497
Filing Date	07/07/2003
First Named Inventor	Doug Hui Huang
Group Art Unit	1632
Examiner Name	

Attorney Docket Number 034827-1303

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,648,482		Meyer	07-15-1997	
	A2	5,981,174		Wolf et al.	11-09-1999	
	A3	6,060,253		Gelboin et al.	05-09-2000	
	A4	6,183,963		Sinnett et al.	02-06-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A5	WO	00/66775		Sumitomo Pharmaceuticals			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A6	Belpaire and Bogaert, Cytochrome P450: genetic polymorphism and drug interactions, Acta Clin Belg 51:254-60, 1996.	
	A7	Bertilsson and Dahl, Polymorphic drug oxidation: Relevance to the treatment of psychiatric disorders, CNS Drugs 5:200-223, 1996.	
	A8	Birgersdotter et al., Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias, Brit J. Clin. Pharmacol. 33:275-280, 1992.	
	A9	Buchert and Woosley, Clinical implications of variable antiarrhythmic drug metabolism, Pharmacogenetics 2:2-11, 1992.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/615,497
				Filing Date	07/07/2003
				First Named Inventor	Doug Hui Huang
				Group Art Unit	1632
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	034827-1303
Sheet	2	of	10		


NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	A10	Chauret et al., In Vitro Comparison of P450-Mediated Metabolic Activities in Human, Dog, Cat, and Horse, Drug Metabolism and Disposition 25:1130-1136, 1997		T ⁶
	A11	Chen et al., CYP2D6 Genotype and the Incidence of Anal and Vulvar Cancer, Cancer Epidemiology, Biomarkers & Prevention 8:317-321, 1999		
	A12	Cholerton et al., Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine, J. Chromatogr. 575, 325-330, 1992		
	A13	Crespi and Miller, The use of heterologously expressed drug metabolizing enzymes—state of the art and prospects for the future, Pharmacology and Therapeutics 84:121-131, 1999		
	A14	Dahl et al., Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis, J Pharmacol Exp Ther 274:516-20, 1995		
	A15	Daly et al., Nomenclature for human CYP2D6 alleles, Pharmacogenetics 6:193-201, 1996		
	A16	Daly, Molecular basis of polymorphic drug metabolism, J. Mol. Med. 73, 539-553, 1995		
	A17	Dayer et al., Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of <i>in vivo</i> phenotyped carriers of the genetic deficiency, Biochem. Pharmacol. 36, 4145-4152, 1988		
	A18	De Morais et al, "Identification of new genetic defect responsible for the polymorphism of (S)-Mephenytoin metabolism in Japanese." Mol. Pharmacol. 46: 594-598, 1994.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/615,497
Filing Date	07/07/2003
First Named Inventor	Doug Hui Huang
Group Art Unit	1632
Examiner Name	

Sheet 3 of 10 Attorney Docket Number 034827-1303

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A19	Dolnik, DNA sequencing by capillary electrophoresis (review), J Biochem Biophys Methods 41:103-19, 1999	
	A20	Dovichi and Zhang, DNA sequencing by capillary array electrophoresis, Methods Mol Biol 167:225-39, 2001	
	A21	Dunning et al., A Systematic Review of Genetic Polymorphisms and Breast Cancer Risk, Cancer Epidemiology, Biomarkers & Prevention 8:843-854, 1999	
	A22	Eichelbaum & Gross, The genetic polymorphism of debrisoquine/sparteine metabolism – clinical aspects, Pharmac. Ther. 46:377-394, 1990	
	A23	Evans et al., The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions, J. Med. Genet 20, 321-329, 1983.	
	A24	Fabian and Degtyarenko, The Directory of P450-containing Systems in 1996, Nucleic Acids Research 25:274-277, 1997	
	A25	Fahy et al., Multiplex fluorescence-based primer extension method for quantitative mutation analysis of mitochondrial DNA and its diagnostic application for Alzheimer's disease, Nucleic Acid Research 25:3102-3109, 1997	
	A26	Fernandez-Salguero et al., A genetic polymorphism in coumarin 7-Hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles, Am. J. Hum. Genet. 57, 651-660, 1995	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/615,497
Filing Date	07/07/2003
First Named Inventor	Doug Hui Huang
Group Art Unit	1632
Examiner Name	

Attorney Docket Number 034827-1303

Sheet

4

of

10

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A27	Fischer et al., The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6, J. Pharmacol. Exp. Ther. 260:1355-1360, 1992	
	A28	Fonne-Pfister and Meyer, Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism, Biochem. Pharmacol. 37:3829-35, 1988	
	A29	Gaedigk et al., Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism, Am. J. Hum. Genet. 48, 943-950, 1991	
	A30	Goldstein and deMorais, Biochemistry and molecular biology of the human CYP2C subfamily, Pharmacogenetics 4: 285-299, 1994.	
	A31	Gonzalez & Gelboin, J., Role of human cytochrome P-450s in risk assessment and susceptibility to environmentally based disease. Journal of Toxicology and Environmental Health 40:289-308, 1993	
	A32	Gonzalez et al., Characterization of the common genetic defect in humans deficient in debrisoquine metabolism, Nature 331:442-446, 1988	
	A33	Gonzalez and Idle, Pharmacogenetic phenotyping and genotyping: Present status and future potential, Clin. Pharmacokin. 26:59-70, 1994.	
	A34	Gonzalez and Gelboin, Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins, Drug, Metab. Rev. 26: 165-183, 1994	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for PTO/SB/08B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/615,497
Filing Date	07/07/2003
First Named Inventor	Doug Hui Huang
Group Art Unit	1632
Examiner Name	

Attorney Docket Number 034827-1303

Sheet

5

of

10


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A35	Gonzalez, The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility, Reproduct. Toxicol. 11, 397-412, 1997.	
	A36	Guengerich et al., Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects, Chem. Res. Toxicol. 4, 168-179, 1991	
	A37	Guidice et al., Evidence for CYP2D6 expression in human lung, Biochem Biophys Res Commun 241:79-85, 1997	
	A38	Hasler et al., Human cytochromes P450, Molecular Aspects of Medicine 20:1-137, 1999	
	A39	Heller, Principles of DNA separation with capillary electrophoresis, Electrophoresis 22:629-43, 2001	
	A40	Hersberger et al., Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR, Clinical Chemistry 46:8, 1072-1077, 2000	
	A41	Hiemke and Hartert, Pharmacokinetics of selective serotonin reuptake inhibitors, Pharmacology & Therapeutics 85:11-28, 2000	
	A42	Hoffman et al., Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome, J. Molec. Evolut. 41, 894-900, 1995	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	6	of	10	Application Number	10/615,497
				Filing Date	07/07/2003
				First Named Inventor	Doug Hui Huang
				Group Art Unit	1632
				Examiner Name	
				Attorney Docket Number	034827-1303


NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A43	Johansson et al., Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine, Proc Natl Acad Sci 90: 11825-11829, 1993			
	A44	Kagimoto et al., Multiple Mutations of the Human Cytochrome P450IID6 Gene (CYP2D6) in Poor Metabolizers of Debrisoquine, J. Biol. Chem. 265:17209-17214, 1990			
	A45	Kalow, Pharmacogenetics in Biological Perspective, Pharmacological Reviews, 49:369-379, 1997.			
	A46	Kashuba ADM, et al., Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. <i>Pharmacogenetics</i> . (1998) 8:403-410			
	A47	Kellermann et al., Arylhydrocarbon hydroxylase and bronchogenic carcinoma, New Eng. J. Med. 289, 934-937, 1973			
	A48	Kroemer and Eichelbaum, "Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism." Life Sci 56:2285-98, 1995			
	A49	LeCluyse, Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation, European Journal of Pharmaceutical Sciences 13: 343-368, 2001			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUBSTITUTE Form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	7	of	10	Attorney Docket Number	034827-1303
-------	---	----	----	------------------------	-------------

Complete if Known

Application Number	10/615,497
Filing Date	07/07/2003
First Named Inventor	Doug Hui Huang
Group Art Unit	1632
Examiner Name	


NON PATENT LITERATURE DOCUMENTS
Examiner Initials* Cite No. ¹ Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. T ⁶
A50 Legrand-Andreoletti et al., Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians, Pharmacogenetics 8:7-14, 1998
A51 Lindblad-Toh et al., Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse. Nature Genet 2000 Apr 024(4):381-6
A52 Linder et al., Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency, Clinical Chemistry 43:254-266, 1997
A53 Lovlie et al., Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene, FEBS lett. 392:30-34, 1996
A54 Lu, Drug-metabolism research challenges in the new millennium, Drug Metabolism And Disposition, 26:12, 1217-1222, 1998
A55 Marez et al., Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution, Pharmacogenetics 7:193-202, 1997
A56 Meldrum, Automation for Genomics, Part Two: Sequencers, Microarrays, and Future Trends, Genome Research, 10:1288-1303, 2000
A57 Mitchelson, "The Application of capillary electrophoresis for DNA polymorphism analysis." Methods Mol Biol 162:3-26, 2001

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/615,497
				Filing Date	07/07/2003
				First Named Inventor	Doug Hui Huang
				Group Art Unit	1632
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	034827-1303
Sheet	8	of	10		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A58	Mogil, The genetic mediation of individual differences in sensitivity to pain and its inhibition, Proc. Natl. Acad. Sci. 96:7744-7751, 1999			T ⁶
	A59	Nasu et al., Genetic analysis of CYP2C9 polymorphism in a Japanese population, Pharmacogenetics 7: 405-409, 1997			
	A60	Nunoya et al., A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502), Pharmacogenetics 8, 239-249, 1998			
	A61	Oliver et al., Use of Single Nucleotide Polymorphisms (SNP) and Real-Time Polymerase Chain Reaction for Bone Marrow Engraftment Analysis, Journal of Molecular Diagnostics 2:202-208, 2000			
	A62	Rautio et al., Interindividual variation of coumarin- hydroxylation in healthy volunteers, Pharmacogenetics 2, 227-233, 1992			
	A63	Sabbagh et al., Genetic analysis of the cytochrome P450 CYP2D6 polymorphism in patients with systemic lupus erythematosus, Pharmacogenetics 8:191-4, 1998			
	A64	Schmitz et al., "Pharmacogenomics: implications for laboratory medicine." Clinica Chimica Acta 308:43-53, 2001			
	A65	Schur et al., Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR, Clinica Chimica Acta 308, 25-31, 2001			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/615,497
				Filing Date	07/07/2003
				First Named Inventor	Doug Hui Huang
				Group Art Unit	1632
				Examiner Name	
Sheet	9	of	10	Attorney Docket Number	034827-1303

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A66	Stephens et al., "Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-American, European-Americans and Taiwanese." <i>Pharmacogenetics</i> 4, 185-192, 1994	
	A67	Stimer et al., <i>Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy</i> , <i>Clinical Chimica Acta</i> 308:33-41, 2001	
	A68	Stubbins et al., Genetic analysis of the human cytochrome P450 CYP2C9 locus, <i>Pharmacogenetics</i> 6, 429-439, 1996	
	A69	Stuven et al., Rapid detection of CYP2D6 null alleles by long distance and multiplex polymerase chain reaction. <i>Pharmacogenetics</i> 6:417-421, 1996	
	A70	Sullivan-Klose et al., The role of the CYP2C9-Leu ³⁵⁹ allelic variant in the tolbutamide polymorphism, <i>Pharmacogenetics</i> 6:341-349, 1996	
	A71	van der Weide et al., Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology, <i>Ann Clin Biochem</i> 36:722-729, 1999	
	A72	Wang et al., Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese, <i>Pharmacogenetics</i> , 5,37-42, 1995	
	A73	Ward et al., The activation of the biguanide antimalarial prguanil co-segregates with the mephenytoin oxidation polymorphism – a panel study, <i>Br. J. Clin. Pharmacol.</i> 31, 689-692, 1991	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form PTO-1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/615,497
				Filing Date	07/07/2003
				First Named Inventor	Doug Hui Huang
				Group Art Unit	1632
				Examiner Name	
Sheet	10	of	10	Attorney Docket Number	034827-1303

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	A74	Weber et al., "Pharmacogenetic Testing," Encyclopedia of Analytical Chemistry, Robert A. Myers editor, John Wiley & Sons Ltd., Chichester; Volume 2, 2000.		T ⁶
	A75	Wilkinson, Cytochrome P4503A (CYP3A) metabolism: prediction of <i>in vivo</i> activity in humans, J Pharmacokinet Biopharm 24:475-90, 1996		
	A76	Wolf et al., Chapter 18. Cytochrome P450 CYP2D6, IARC Sci Publ 148:209-29, 1999		
	A77	Yasar et al., Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628-31, 1999 (abstract).		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.